Key Points
- Humana insider Joseph Ventura sold 5,495 shares for about $2.38 million, reducing his stake by 20.05% to 21,910 shares.
- Humana’s latest quarter beat analyst estimates: adjusted earnings were $0.30 per share better than expected, and revenue of $41.16 billion exceeded forecasts and rose 26.1% year over year.
- Analysts’ consensus rating is “Moderate Buy”, with an average price target of $476.52; Humana also declared a quarterly dividend of $0.885 per share.
Humana Inc. (NYSE:HUM - Get Free Report) insider Joseph Ventura sold 5,495 shares of the stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $433.85, for a total value of $2,384,005.75. Following the transaction, the insider owned 21,910 shares in the company, valued at $9,505,653.50. This trade represents a 20.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Humana Stock Performance
Shares of NYSE HUM opened at $442.67 on Friday. The stock has a market cap of $53.17 billion, a price-to-earnings ratio of 33.66, a P/E/G ratio of 2.12 and a beta of 0.65. The company has a current ratio of 1.65, a quick ratio of 1.74 and a debt-to-equity ratio of 0.61. Humana Inc. has a 1-year low of $163.11 and a 1-year high of $456.50. The stock's 50-day moving average is $407.64 and its 200 day moving average is $315.70.
Humana (NYSE:HUM - Get Free Report) last released its earnings results on Friday, November 6th. The insurance provider reported ($0.70) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.30. The company had revenue of $41.16 billion during the quarter, compared to the consensus estimate of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. Humana's quarterly revenue was up 26.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. On average, sell-side analysts anticipate that Humana Inc. will post 9.69 EPS for the current fiscal year.
Humana Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 29th. Shareholders of record on Thursday, December 24th will be paid a dividend of $0.8850 per share. The ex-dividend date of this dividend is Thursday, December 24th. This represents a $3.54 annualized dividend and a dividend yield of 0.8%. Humana's dividend payout ratio (DPR) is 34.44%.
Analysts Set New Price Targets
A number of brokerages recently commented on HUM. Raymond James Financial reiterated an "outperform" rating on shares of Humana in a research report on Friday, November 6th. Zacks Research upgraded shares of Humana from a "hold" rating to a "strong-buy" rating in a research report on Tuesday. Monness Crespi & Hardt upgraded shares of Humana to a "buy" rating in a research report on Friday, October 9th. Wells Fargo & Company raised their price objective on Humana from $502.00 to $602.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, Wall Street Zen upgraded Humana from a "hold" rating to a "buy" rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Humana currently has a consensus rating of "Moderate Buy" and an average price target of $476.52.
Read Our Latest Stock Report on HUM
Humana News Roundup
These are some of the HUM news items that stood out recently:
- Positive Sentiment: Humana’s new oncology care model is intended to accelerate cancer treatment and reduce administrative hurdles, potentially supporting its broader value-based-care strategy. Zacks oncology model article
- Neutral Sentiment: TD Cowen raised its price target to $430 from $370 but maintained a “hold” rating; its target is below the cited share price, signaling a more cautious view than other recent analyst calls.
- Negative Sentiment: A law firm invited Humana shareholders to discuss their rights concerning a potential fiduciary-duty matter. The notice provides no specific findings, so it indicates a legal inquiry rather than established wrongdoing. PR Newswire notice
Institutional Trading of Humana
A number of institutional investors have recently made changes to their positions in HUM. Johnson Financial Group Inc. bought a new position in shares of Humana in the second quarter worth approximately $26,000. Trust Co. of Vermont purchased a new position in shares of Humana in the second quarter worth $28,000. Bogart Wealth LLC raised its holdings in Humana by 192.0% during the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider's stock valued at $29,000 after buying an additional 48 shares during the last quarter. MidFirst Bank bought a new stake in Humana during the 2nd quarter valued at $35,000. Finally, Global Assets Advisory LLC bought a new stake in Humana during the 1st quarter valued at $38,000. Hedge funds and other institutional investors own 92.38% of the company's stock.
Humana Company Profile
(
Get Free Report)
Humana Inc. is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans. The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
